Cary Street Partners Investment Advisory’s BeOne Medicines Ltd ONC Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.12K	Buy	+25	New	+$7.37K	﹤0.01%	701

Other funds holding ONC

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Cary Street Partners Investment Advisory's ONC Position: Q2 2026 in Review

Cary Street Partners Investment Advisory opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 25 shares worth $7.12K. The stake represents ﹤0.01% of the portfolio and ranks #701 among its holdings.

147 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Cary Street Partners Investment Advisory held 25 shares of BeOne Medicines Ltd worth $7.12K as of Q2 2026.
BeOne Medicines Ltd was a new Cary Street Partners Investment Advisory position in Q2 2026.
BeOne Medicines Ltd made up ﹤0.01% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #701 holding.
147 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.